• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.多剂量消旋羟氯喹给药后类风湿关节炎患者体内羟氯喹对映体的处置情况。
Br J Clin Pharmacol. 1993 Jul;36(1):78-81. doi: 10.1111/j.1365-2125.1993.tb05897.x.
2
Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate.接受多剂量消旋羟氯喹的类风湿性关节炎患者中羟氯喹对映体的药代动力学和药效学
Chirality. 1994;6(4):355-9. doi: 10.1002/chir.530060420.
3
Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate.消旋体单剂量给药后羟基氯喹对映体的处置与吸收
Chirality. 1994;6(4):360-4. doi: 10.1002/chir.530060421.
4
Stereoselective distribution of hydroxychloroquine in the rabbit following single and multiple oral doses of the racemate and the separate enantiomers.消旋体及其单一对映体单次及多次口服给药后,羟氯喹在兔体内的立体选择性分布。
Chirality. 1994;6(4):337-46. doi: 10.1002/chir.530060418.
5
Stereoselective disposition of hydroxychloroquine and its metabolite in rats.羟氯喹及其代谢物在大鼠体内的立体选择性分布。
Chirality. 1995;7(8):598-604. doi: 10.1002/chir.530070807.
6
Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients.类风湿关节炎患者中羟氯喹的稳态药代动力学
DICP. 1991 Dec;25(12):1302-5. doi: 10.1177/106002809102501202.
7
Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects.健康受试者单次口服消旋体后羟氯喹的对映体选择性处置。
Br J Clin Pharmacol. 1995 Aug;40(2):127-33. doi: 10.1111/j.1365-2125.1995.tb05768.x.
8
Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.实验性糖尿病和关节炎对大鼠体内羟氯喹对映体药代动力学的影响。
Pharm Res. 1998 Jun;15(6):897-903. doi: 10.1023/a:1011928732588.
9
Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis.类风湿性关节炎患者中布洛芬立体选择性处置的变异性。
Br J Clin Pharmacol. 1993 Jun;35(6):603-7. doi: 10.1111/j.1365-2125.1993.tb04189.x.
10
Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis.
Br J Rheumatol. 1994 Mar;33(3):235-9. doi: 10.1093/rheumatology/33.3.235.

引用本文的文献

1
A New Comparison of the Relative Affinity of Enantiomeric Chloroquine (CQ) and Hydroxychloroquine (HCQ) for ACE2.对映体氯喹(CQ)和羟氯喹(HCQ)与ACE2相对亲和力的新比较
Pharmaceuticals (Basel). 2025 Jun 30;18(7):982. doi: 10.3390/ph18070982.
2
Dissimilar effects of stereoisomers and racemic hydroxychloroquine on Ca oscillations in human induced pluripotent stem cell-derived cardiomyocytes.立体异构体和外消旋羟氯喹对人诱导多能干细胞衍生心肌细胞钙振荡的不同影响。
Physiol Rep. 2023 Jul;11(14):e15760. doi: 10.14814/phy2.15760.
3
Biomimetic properties and estimated in vivo distribution of chloroquine and hydroxy-chloroquine enantiomers.氯喹和羟基氯喹对映体的仿生特性及体内分布估计
ADMET DMPK. 2020 Jan 25;9(2):151-165. doi: 10.5599/admet.929. eCollection 2021.
4
Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.合成并评估了对 SARS-CoV-2 具有体外抑制活性的羟氯喹对映异构体。
Bioorg Med Chem. 2022 Jan 1;53:116523. doi: 10.1016/j.bmc.2021.116523. Epub 2021 Nov 22.
5
Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers.发展一种手性 HPLC 方法用于分离和定量羟氯喹对映异构体。
Sci Rep. 2021 Apr 13;11(1):8017. doi: 10.1038/s41598-021-87511-5.
6
Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.羟氯喹啉基于生理的药代动力学模型的建立及其在特定COVID-19患者剂量优化中的应用
Front Pharmacol. 2021 Feb 12;11:585021. doi: 10.3389/fphar.2020.585021. eCollection 2020.
7
Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.羟氯喹治疗 RNA 病毒和慢性疾病的临床和临床前研究现状:系统评价。
Molecules. 2020 Nov 14;25(22):5318. doi: 10.3390/molecules25225318.
8
A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.用超临界流体色谱法对羟氯喹进行制备手性分离。
J Chromatogr A. 2020 Dec 20;1634:461661. doi: 10.1016/j.chroma.2020.461661. Epub 2020 Oct 29.
9
Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.新冠疫情下药物的重新利用:氯喹和羟氯喹的药代动力学和药物基因组学
Pharmgenomics Pers Med. 2020 Oct 23;13:531-542. doi: 10.2147/PGPM.S275964. eCollection 2020.
10
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.氯喹和羟氯喹在新型冠状病毒肺炎感染背景下的药代动力学及药理特性
Clin Pharmacol Ther. 2020 Dec;108(6):1135-1149. doi: 10.1002/cpt.1993. Epub 2020 Sep 1.

本文引用的文献

1
High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection.采用聚(苯乙烯-二乙烯基苯)固定相和pH 11的流动相,通过荧光检测对血液和血浆中的羟氯喹及其代谢物进行高效液相色谱分析。
J Chromatogr. 1985 Nov 8;344:241-8. doi: 10.1016/s0378-4347(00)82024-1.
2
Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine.口服消旋氯喹后氯喹和去乙基氯喹的对映体选择性分析。
Ther Drug Monit. 1986;8(4):457-61. doi: 10.1097/00007691-198612000-00014.
3
A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.一项对健康志愿者静脉注射羟氯喹后药代动力学的剂量范围研究。
Br J Clin Pharmacol. 1988 Sep;26(3):303-13. doi: 10.1111/j.1365-2125.1988.tb05281.x.
4
Bioavailability of hydroxychloroquine tablets in healthy volunteers.羟氯喹片在健康志愿者中的生物利用度。
Br J Clin Pharmacol. 1989 Jun;27(6):771-9. doi: 10.1111/j.1365-2125.1989.tb03439.x.
5
High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an alpha 1-acid glycoprotein stationary phase.使用α1-酸性糖蛋白固定相通过高效液相色谱法分离生物流体中羟氯喹及其主要代谢物的对映体。
J Chromatogr. 1991 Sep 18;570(1):119-27. doi: 10.1016/0378-4347(91)80206-r.
6
[Chloroquine enantiomers. Activity against P. vinckei and binding on DNA (author's transl)].
Arzneimittelforschung. 1979;29(1):163-4.
7
Antimalarial activity of the optical isomers of chloroquine diphosphate.
Tropenmed Parasitol. 1979 Sep;30(3):308-12.

多剂量消旋羟氯喹给药后类风湿关节炎患者体内羟氯喹对映体的处置情况。

Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.

作者信息

McLachlan A J, Tett S E, Cutler D J, Day R O

机构信息

Department of Pharmacy, University of Sydney, NSW, Australia.

出版信息

Br J Clin Pharmacol. 1993 Jul;36(1):78-81. doi: 10.1111/j.1365-2125.1993.tb05897.x.

DOI:10.1111/j.1365-2125.1993.tb05897.x
PMID:8373715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1364560/
Abstract

In eight patients with rheumatoid arthritis receiving racemic hydroxychloroquine, blood and urine concentrations of the enantiomers of hydroxychloroquine and its major metabolites were measured each month over the first 6 months of therapy. Plasma concentrations of hydroxychloroquine enantiomers were measured in five of these patients. In all patients, the blood concentration of (R)-hydroxychloroquine exceeded that of the (S)-enantiomer, the mean (R)/(S) ratio being 2.2 (range 1.6-2.9). A similar excess of (R)-hydroxychloroquine was found in the plasma, the mean (R)/(S) ratio being 1.6 (range 1.2-1.9). The mean enantiomer blood concentration ratio (R)/(S) for the metabolite desethylhydroxychloroquine was 0.45 (range 0.34-0.58) and for desethylchloroquine it was 0.56 (range 0.35-0.86) suggesting stereoselective metabolism of hydroxychloroquine. (S)-hydroxychloroquine had a mean (+/- s.d.) renal clearance from blood of 41 +/- 11 ml min-1, approximately twice that of (R)-hydroxychloroquine. The predicted unbound renal clearance was also higher for (S)-hydroxychloroquine. The clinical implications of enantioselective disposition of hydroxychloroquine are currently not known.

摘要

在8例接受消旋羟氯喹治疗的类风湿性关节炎患者中,在治疗的前6个月每月测定羟氯喹对映体及其主要代谢产物的血药浓度和尿药浓度。对其中5例患者测定了羟氯喹对映体的血浆浓度。在所有患者中,(R)-羟氯喹的血药浓度超过(S)-对映体,平均(R)/(S)比值为2.2(范围1.6 - 2.9)。在血浆中也发现(R)-羟氯喹有类似的过量情况,平均(R)/(S)比值为1.6(范围1.2 - 1.9)。代谢产物去乙基羟氯喹的对映体血药浓度平均比值(R)/(S)为0.45(范围0.34 - 0.58),去乙基氯喹的为0.56(范围0.35 - 0.86),提示羟氯喹存在立体选择性代谢。(S)-羟氯喹从血液中的平均(±标准差)肾清除率为41±11 ml·min⁻¹,约为(R)-羟氯喹的两倍。(S)-羟氯喹的预测非结合肾清除率也更高。目前尚不清楚羟氯喹对映体选择性处置的临床意义。